Karo Strengthens Foot Care Offering As It Closes Lamisil Deal

Sweden's Karo has extended its footprint and geographical reach into new markets by closing its acquisition of topical antifungal brand Lamisil from Haleon.

feet at edge of pool
• Source: Shutterstock

Karo Healthcare says it has significantly strengthened its position in the OTC foot-care category after closing its acquisition of topical antifungal brand Lamisil from Haleon.

More from Deals

Alliance Pharma Takeover Wins Shareholder Backing After Increased Offer

 
• By 

Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.

VC Fund Spies Opportunity In ‘Overlooked’ Consumer Health Market

 
• By 

Venture capital fund backed by Germany's Schwabe has €100m to invest in consumer health startups operating in categories such as sleep and mental health.

Cooper Partners With MagnaPharm For Central and Eastern Europe Distribution

 
• By 

Cooper takes another step in its international expansion strategy through a partnership with Romania’s MagnaPharm for the distribution and commercialization of its self-care brand portfolio in Central and Eastern Europe (CEE).

Cooper Partners With Conaxess For Nordics Distribution

 
• By 

The Aurelius-owned distributor will create a new business unit especially for this purpose, headed up by business director Patrik Hene.

More from Business

Alliance Pharma Takeover Wins Shareholder Backing After Increased Offer

 
• By 

Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.

New Product Launches Ensured Growth For Stada CHC In 2024

 
• By 

Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.

Bayer Consumer Health Outlook Accelerated By ‘Dynamic’ Cuts To Staff Layers, Efficiency Boost

 

Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."